Enoticumab

仅用于工业应用或科学研究，不可用于人类或动物的临床诊断或治疗，非药用. Enoticumab （REGN421, SAR153192） is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 （2.5 mg/kg once weekly） resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively